Department of Nephrology, Hospital Universitario de la Princesa, Madrid, Spain.
J Med Virol. 2010 May;82(5):763-7. doi: 10.1002/jmv.21469.
Hemodialysis induces production of the hepatocyte growth factor (HGF) and decrease of serum hepatitis C virus (HCV) RNA in patients with HCV infection, but it is not known if the hemodialysis schedule or type of membrane affect both the HGF production and HCV viremia. The effects on both parameters of alternate-day intermittent hemodialysis and short-daily hemodialysis and high and low flux membranes were investigated in 41 patients treated by hemodialysis. Sixteen (39%) patients were anti-HCV positive and 11 (69%) had HCV RNA. Twenty-six patients were on alternate-day intermittent and 15 on short-daily hemodialysis. High flux membranes were used for 29 patients and low flux membranes for 12 patients. A decrease in HCV RNA was observed at the end of hemodialysis (8.6 x 10(5) +/- 1.1 x 10(6) IU/ml vs. 4.4 x 10(5) +/- 7.3 x 10(5) IU/ml, P = 0.003). The proportion of HCV RNA decrease was similar in patients dialyzed with both schedules and with both types of membranes. The HGF levels increased from 2,605.9 +/- 1,428.7 to >8,000 pg/ml at 15 min. At the end of the session, the HGF levels decreased to 5,106.7 +/- 2,533.9 pg/ml. The HGF levels at the start of the next session were similar to those at baseline (2,680.0 +/- 1,209.3 pg/ml). The increase and dynamics of the HGF levels were similar in patient's hemodialyzed with both schedules and with both types of membranes. These results suggest that changes in HCV RNA and HGF levels during hemodialysis are not influenced by the schedule or type of membrane used.
血液透析可诱导丙型肝炎病毒（HCV）感染患者产生肝细胞生长因子（HGF）并降低血清 HCV RNA，但尚不清楚血液透析方案或膜类型是否会影响 HGF 产生和 HCV 病毒血症。本研究观察了 41 例接受血液透析治疗的患者，分别采用隔日间歇性血液透析和短日血液透析及高通量和低通量膜对两种参数的影响。16 例（39%）患者抗 HCV 阳性，11 例（69%）有 HCV RNA。26 例患者行隔日间歇性血液透析，15 例行短日血液透析。29 例患者使用高通量膜，12 例患者使用低通量膜。血液透析结束时观察到 HCV RNA 下降（8.6×10^5±1.1×10^6IU/ml比 4.4×10^5±7.3×10^5IU/ml，P=0.003）。两种方案和两种膜类型的患者 HCV RNA 下降比例相似。HGF 水平在 15 分钟时从 2605.9±1428.7 pg/ml 升高至>8000 pg/ml。透析结束时，HGF 水平下降至 5106.7±2533.9 pg/ml。下一疗程开始时的 HGF 水平与基线相似（2680.0±1209.3 pg/ml）。两种方案和两种膜类型的患者 HGF 水平的升高和动态变化相似。这些结果表明，血液透析过程中 HCV RNA 和 HGF 水平的变化不受所使用的方案或膜类型的影响。
